BioInvent has Submitted a CTA for a Phase 1/2a trial of BI-1607, a Novel anti-FcyRIIB Antibody for the Treatment of Patients with Solid Tumors

BioInvent has Submitted a CTA for a Phase 1/2a trial of BI-1607, a Novel anti-FcyRIIB Antibody for the Treatment of Patients with Solid Tumors
phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.